COMP <GO>
OM vs LLY // EV/EBITDA & P/E VALUATION
Outset Medical Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: OM 0
— LLY 9
■ METRIC PARITY
LAST: $4.19 (-3.46%) • MKT CAP: $78.8M
valuation
—
LAST: $1,373.70 (+6.63%) • MKT CAP: $1.29T
valuation
36.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (OM VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | OM | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 39.10% | 83.64% | -44.54 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -28.00% | 32.36% | -60.36 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 36.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | 2.30% | — | TIE | /fcf-yield <GO> |
| Operating Margin | -55.80% | 40.21% | -96.01 | LLY | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 31.90% | -91.90 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 5.10% | 45.51% | -40.41 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 9.29 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 9/9 | -3.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 51.8 | 66.6 | -14.81 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.51 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 26.3x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $78.8M | $1.29T | -$1.29T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | OM REV | LLY REV | OM GROSS % | LLY GROSS % | OM FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $119.5M | $65.18B | 39.1% | 83.0% | -$47.1M | $16.81B |
| FY 2024 | $113.7M | $45.04B | 33.9% | 81.3% | -$117.2M | $8.82B |
| FY 2023 | $130.4M | $34.12B | — | 79.3% | -$131.4M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
OM // BETA —
LLY // BETA 0.51